Daniel Lang Net Worth

The estimated Net Worth of Daniel Lang is at least $17.2 ezer dollars as of 16 September 2022. Daniel Lang owns over 12,500 units of Athenex Inc stock worth over $17,183 and over the last 2 years he sold ATNX stock worth over $0. In addition, he makes $0 as Senior Director - Corporate Development és President - Axis Therapeutics Limited at Athenex Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Daniel Lang ATNX stock SEC Form 4 insiders trading

Daniel has made over 1 trades of the Athenex Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 12,500 units of ATNX stock worth $2,500 on 16 September 2022.

The largest trade he's ever made was exercising 12,500 units of Athenex Inc stock on 16 September 2022 worth over $2,500. On average, Daniel trades about 6,250 units every 0 days since 2022. As of 16 September 2022 he still owns at least 85,913 units of Athenex Inc stock.

You can see the complete history of Daniel Lang stock trades at the bottom of the page.

Daniel Lang biography

Dr. Daniel Lang M.D. serves as Senior Director - Corporate Development, President - Axis Therapeutics Limited of the Company. Dr. Lang joins Axis and Athenex to lead the operations of the company's T-cell receptor-engineered T cells (TCR-T) immunotherapy platform for oncology and to assist with corporate development strategy for Athenex. In this new role, Dr. Lang will report to Dr. Johnson Lau, Chief Executive Officer of Athenex and Axis, and will work closely with the management teams of both companies. Dr. Lang has more than 25 years of experience as a physician, scientist and investor. Most recently, he was the Chief Investment Officer of RS Value, an investment franchise of Victory Capital, overseeing the RS Value strategies, as well as an analyst and portfolio manager for healthcare investments since 2009. Prior to RS Value, Dr. Lang was an analyst at Farallon Capital Management, a global multi-strategy hedge fund, responsible for healthcare investments. Dr. Lang started his career as a physician scientist, completing a cardiology fellowship at the University of California, San Francisco. He earned his B.A. in Chemistry from Cornell University and M.D. from Weill Cornell Medical College.

What's Daniel Lang's mailing address?

Daniel's mailing address filed with the SEC is C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO, NY, 14203.

Insiders trading at Athenex Inc

Over the last 7 years, insiders at Athenex Inc have traded over $33,215,399 worth of Athenex Inc stock and bought 5,920,005 units worth $73,651,360 . The most active insiders traders include Advisors Llcperceptive Life..., Song Yi Zhang és Song Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of $10,843. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth $125.

What does Athenex Inc do?

athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.

Complete history of Daniel Lang stock trades at Athenex Inc

Athenex Inc executives and stock owners

Athenex Inc executives and other stock owners filed with the SEC include:

• Johnson Lau,
  Chief Executive Officer and Chairman of the Board
• Rudolf Kwan,
  Chief Medical Officer
• Jeffrey Yordon,
  Chief Operating Officer and President, Athenex Pharmaceutical Division
• Randoll Sze,
  Chief Financial Officer
• Simon Pedder,
  Chief Business and Strategy Officer - Proprietary Products
• Jeffrey M. Yordon,
  COO & Pres of Athenex Pharmaceutical Division
• Dr. Rudolf Kwan M.D., M.B., B.S.,
  Chief Medical Officer
• Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D.,
  Chairman & CEO
• Benson Tsang,
  Independent Director
• Stephanie Davis,
  Independent Director
• Kim Campbell,
  Lead Independent Director
• Jinn Wu,
  Independent Director
• Jordan Kanfer,
  Independent Director
• John Vierling,
  Independent Director
• Manson Fok,
  Director
• Robert Spiegel,
  Director
• Daniel Lang,
  Senior Director - Corporate Development, President - Axis Therapeutics Limited
• Tim McCarthy,
  IR Contact Officer
• William Zuo,
  President, China Division
• Dr. Wing-Kai Chan,
  Deputy Chief Medical Officer of Orascovery & Src Kinase Platforms
• John W. Matthei,
  VP of HR
• Caileigh Dougherty,
  Director of Investor Relations
• Michael Smolinski Ph.D.,
  Chief Scientific Officer
• Steven J. Adams,
  Interim Chief Accounting Officer
• Daniel Lang M.D.,
  Sr. Director of Corp. Devel.
• Jacqueline Li,
  Director of Corp. Devel. & Investor Relations
• Steven Rubis,
  Sr. Director of Investor Relations
• Teresa Brophy Bair,
  Gen. Counsel, Sr. VP of Admin. & Corp. Sec.
• Dr. Allen Barnett,
  Co-Founder & Pres Emeritus
• James Zukin,
  
• Michael D Cannon,
  
• J Nick Riehle,
  Chief Financial Officer
• Antony Leung,
  
• Song Yi Zhang,
  Director
• John Koh,
  Director
• Advisors Llcperceptive Life...,
  
• Sheldon Trainor Degirolamo,
  Director
• Timothy De Vere Cook,
  See Remarks
• Teresa Brophy Bair,
  General Counsel, SVP Admin.
• Joe Annoni,
  Chief Financial Officer
• Steven J. Adams,
  Interim Chief Acct Officer
• Michael Smolinski,
  Chief Scientific Officer